PMGC Holdings (ELAB) Short term Debt (2023 - 2026)

PMGC Holdings (ELAB) posted Short term Debt of $5.2 million for Q1 2026, up 317.35% sequentially from $1.3 million in Q4 2025.

PMGC Holdings (ELAB) Short term Debt (2023 - 2026) Analysis & Trends

PMGC Holdings has reported Short term Debt for 4 years, with the latest figure at $5.2 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
Short term Debt climbed to $5.2 million in Q1 2026 per ELAB's latest filing, from $1.3 million in the prior quarter.
Over five years, Short term Debt peaked at $5.2 million in Q1 2026 and troughed at $77127.0 in Q4 2023.
A 4-year average of $1.5 million and a median of $350000.0 in 2024 frame the typical range for Short term Debt.
The widest YoY moves for Short term Debt: up 812.59% in 2025, down 812.59% in 2025.
Over 4 years, Short term Debt stood at $77127.0 in 2023, then jumped by 353.8% to $350000.0 in 2024, then surged by 258.42% to $1.3 million in 2025, then surged by 317.35% to $5.2 million in 2026.
According to Business Quant data, Short term Debt over the past three periods registered $5.2 million, $1.3 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.78 Bn	131.93 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.58 Bn	78.59 Bn	3.93 Bn
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn
4	Moderna	58.86 Bn	53.73 Bn	52.00 Mn
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.73 Bn	28.42 Bn	992.69 Mn
7	BioNTech SE	28.19 Bn	9.80 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.24 Bn	26.41 Bn	-
10	PMGC Holdings	30.82 Mn	12.03 Mn	385,691.00

Download Data